We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

By LabMedica International staff writers
Posted on 07 Aug 2026

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. More...

Although highly effective antiviral therapies are available, persistent gaps in screening, confirmatory testing, and linkage to care continue to limit disease control. New findings show that a countywide precision screening program combined with decentralized treatment substantially improved case detection, treatment initiation, and projected health outcomes.

National Taiwan University and collaborating institutions developed an integrated hepatitis C elimination program across Changhua County, Taiwan, combining risk-based screening with decentralized, community-based care. Rather than relying solely on population-wide screening, the model prioritizes high-risk groups, including people with chronic kidney disease, diabetes, human immunodeficiency virus (HIV), individuals who inject drugs, incarcerated populations, and dialysis patients. Services are embedded within existing community health resources and integrate targeted screening, rapid diagnosis, confirmatory RNA testing, and locally delivered treatment.

In a study involving more than 1.27 million residents, published in Nature Communications, the program increased hepatitis C screening coverage from 53.7% to 90.2%. Confirmatory RNA testing doubled, treatment initiation reached 91.6%, and modern antiviral therapy achieved a 99% cure rate. Advanced statistical modeling projected reductions in liver cancer incidence and liver-related mortality sufficient to meet World Health Organization (WHO) hepatitis C elimination targets by 2030.

For clinical laboratories, the targeted approach increased demand for confirmatory RNA testing while directing diagnostic resources toward populations with the highest pretest probability. The Changhua program demonstrates how precision public health, integrated care networks, and data-driven decision-making can improve progression from screening through treatment and accelerate hepatitis C elimination.

“Our study demonstrates that hepatitis C elimination depends not only on effective medicines but also on delivering the right care to the right people at the right time. By integrating precision risk-based screening with community-based health care, we provide a practical model that can help countries worldwide accelerate progress toward hepatitis C elimination,” said co-corresponding author Tony Hsiu-Hsi Chen of the Institute of Health Data Analytics and Statistics at National Taiwan University.

Related Links
National Taiwan University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Automated Immunoassay Analyzer
SuperFlex™
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.